Skip to main content
Ascletis Pharma Inc. logo

Ascletis Pharma Inc. — Investor Relations & Filings

Ticker · 1672 ISIN · KYG0520K1094 LEI · 254900SKEFCO9I3GPL05 HKEX Manufacturing
Open in API
Filings indexed 1,473 across all filing types
Latest filing 2021-04-07 Capital/Financing Update
Country KY Cayman Islands
Listing HKEX 1672

About Ascletis Pharma Inc.

http://www.ascletis.com

Ascletis Pharma Inc. is a fully integrated, R&D driven biotechnology company dedicated to the development and commercialization of potential best-in-class and first-in-class therapeutics. The company covers the entire value chain from discovery to sales. Ascletis primarily focuses on metabolic diseases, including chronic weight management, utilizing proprietary platforms such as Artificial Intelligence-assisted Structure-Based Drug Discovery (AISBDD), Ultra-Long-Acting Platform (ULAP), and Peptide Oral Transport ENhancement Technology (POTENT). Key pipeline candidates include ASC30 (oral/subcutaneous GLP-1R agonist), ASC35 (GLP-1R/GIPR dual agonist), ASC36 (amylin receptor agonist), and ASC37 (GLP-1R/GIPR/GCGR triple agonist). The company also maintains active programs in viral diseases, NASH/PBC, and oncology.

Recent filings

Filing Released Lang Actions
Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 March 2021
Capital/Financing Update Classification · 95% confidence The document is titled 'Monthly Return of Equity Issuer on Movements in Securities' for the month ended 31/3/2021, submitted to the Hong Kong Exchanges and Clearing Limited. It details movements in authorized share capital, issued share capital, share options, warrants, convertibles, and other share-related transactions. The content focuses on changes in the company's capital structure and share issuance activities during the month. There is no indication of financial performance data, earnings, management discussion, or audit information. The document is a regulatory filing reporting share capital movements and related confirmations to the stock exchange. This fits the definition of a Capital/Financing Update (CAP) as it provides updates on company fundraising, financing activities, or capital structure changes.
2021-04-07 English
Monthly Return of Equity Issuer on movements in Securities for the month ended 31 March 2021
Share Issue/Capital Change Classification · 95% confidence The document is titled 'Monthly Return of Equity Issuer on Movements in Securities' for the month ended 31/03/2021 and is addressed to the Hong Kong Exchanges and Clearing Limited. It details movements in authorised share capital, issued share capital, share options, warrants, convertibles, and other movements in issued share capital. The content focuses on changes in the company's share capital structure during a specific month. There is no indication that this is an annual or quarterly financial report, audit report, or earnings release. It is a regulatory filing reporting share capital movements, which fits the category of Share Issue/Capital Change (SHA). The document is substantive and not merely an announcement or certification, so it is not RPA or RNS. Therefore, the classification is SHA with high confidence.
2021-04-07 English
GRANT OF SHARE OPTIONS
Share Issue/Capital Change Classification · 95% confidence The document is an announcement regarding the grant of share options by Ascletis Pharma Inc. It details the number of options granted, the exercise price, the grant date, and the validity period. It references compliance with the Listing Rules of the Hong Kong Stock Exchange. The document is short (2754 characters) and is clearly an announcement of a share option grant, which is a capital-related event but not a full report or financial statement. It does not contain financial results or detailed financial data. Therefore, it fits best under the category of Share Issue/Capital Change (SHA), which covers announcements regarding new share issues or capital changes such as share options.
2021-03-31 English
RESULTS ANNOUNCEMENT FOR THE YEAR ENDED 31 DECEMBER 2020
Annual Report Classification · 100% confidence The document is a detailed financial report containing audited consolidated financial results for the year ended 31 December 2020, including comprehensive financial statements such as the consolidated statement of profit or loss, statement of financial position, segment information, notes on accounting policies, and amendments to financial reporting standards. The presence of full financial data, comparative figures for the prior year, and detailed notes indicates this is a full annual financial report. The document is not a brief announcement or a certification letter, nor is it a transcript, presentation, or voting result. Therefore, it fits the definition of an Annual Report (10-K equivalent). FY 2020
2021-03-30 English
ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED DECEMBER 31, 2020
Annual Report Classification · 95% confidence The document is titled 'ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED DECEMBER 31, 2020' and contains detailed financial highlights, including revenue, profit/loss figures, and loss per share for the full fiscal year 2020 compared to 2019. It also includes extensive business and pipeline descriptions, management discussion and analysis of the company's progress, clinical trials, and product development. The length is substantial (15,000 characters), and the content includes actual financial data and management commentary, not just an announcement or summary. This matches the characteristics of an Annual Report or a comprehensive annual financial disclosure. The document is not a brief earnings release (which would be shorter and less detailed), nor is it a regulatory filing or announcement of report publication. Therefore, the most appropriate classification is Annual Report (10-K). FY 2020
2021-03-30 English
INSIDE INFORMATION - INVESTMENT ESCALATION IN THE R&D OF CANCER LIPID METABOLISM AND ORAL CHECKPOINT INHIBITORS AND PROPOSED INITIATION OF A PIVOTAL PHASE II TRIAL OF ASC40 IN COMBINATION WITH BEV
Regulatory Filings Classification · 95% confidence The document is an announcement by Ascletis Pharma Inc. regarding an investment escalation in R&D and the proposed initiation of a pivotal Phase II clinical trial. It is labeled as "INSIDE INFORMATION" and references regulatory rules under the Hong Kong Stock Exchange Listing Rules and Securities and Futures Ordinance. The content focuses on strategic R&D investment and clinical trial plans, not on financial results or detailed financial statements. The document is about corporate developments and pipeline updates rather than financial reporting or management changes. It is not a full financial report, earnings release, or management discussion. It is also not a regulatory certification or voting result. Given the nature of the announcement—disclosing material inside information about R&D investment and clinical trial initiation—it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2021-03-30 English

Browse filings by year

28 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.